Tampilkan postingan dengan label Metabolic. Tampilkan semua postingan
Tampilkan postingan dengan label Metabolic. Tampilkan semua postingan

Sabtu, 11 Februari 2017

EARLY ANTIBIOTIC EXPOSURE LEADS TO LIFE LONG METABOLIC DISTURBANCE IN MICE



A new study published in Cell suggests that antibiotic exposure during a critical window of early development disrupts the bacterial landscape of the gut, home to trillions of diverse microbes, and permanently reprograms the body's metabolism, setting up a predisposition to obesity. Moreover, the study shows that it is altered gut bacteria, rather than the antibiotics, driving the metabolic effects.

The new study by NYU Langone Medical Center researchers reveals that mice given lifelong low doses of penicillin starting in the last week of pregnancy or during nursing were more susceptible to obesity and metabolic abnormalities than mice exposed to the antibiotic later in life.
Most intriguing, in a complementary group of experiments, mice given low doses of penicillin only during late pregnancy through nursing gained just as much weight as mice exposed to the antibiotic throughout their lives.

"We found that when you perturb gut microbes early in life among mice and then stop the antibiotics, the microbes normalize but the effects on host metabolism are permanent," says senior author Martin Blaser, MD, the Muriel G. and George W. Singer Professor of Translational Medicine, director of the NYU Human Microbiome Program, and professor of microbiology at NYU School of Medicine. "This supports the idea of a developmental window in which microbes participate. It's a novel concept, and we're providing direct evidence for it."

The researchers stress that more evidence is needed before it can be determined whether antibiotics lead to obesity in humans, and the present study should not deter doctors from prescribing antibiotics to children when they are necessary. "The antibiotic doses used in this study don't mirror what children get," says Laura M. Cox, PhD, a postdoctoral fellow in Dr. Blaser's laboratory and the lead author of the study. "But it has identified an early window in which microbes can influence metabolism, and so further studies are clearly warranted."

In one experiment in the study, Dr. Cox administered water with low doses of penicillin to three groups of mice. One group received antibiotics in the womb during the last week of pregnancy and continued the medication throughout life. The second group received the same dose of penicillin after weaning and, like the first group, continued it throughout life. The third received no antibiotics. "We saw increased fat mass in both penicillin groups, but it was higher in the mice who received penicillin starting in the womb," Dr. Cox says. "This showed that mice are more metabolically vulnerable if they get antibiotics earlier in life."
The treated mice also grew fatter than the untreated mice when both were fed a high-fat diet. "When we put mice on a high-calorie diet, they got fat. When we put mice on antibiotics, they got fat," explains Dr. Blaser. "But when we put them on both antibiotics and a high-fat diet, they got very, very fat." Normally, adult female mice carry three grams of fat. The animals in the study fed the high-fat diet had five grams of fat. By comparison, the mice who received antibiotics plus the high-fat chow packed on 10 grams of fat, accounting for a third of their body weight. The treated rodents were not only fatter but also suffered elevated levels of fasting insulin, and alterations in genes related to liver regeneration and detoxification -- effects consistent with metabolic disorders in obese patients.

This work confirms and extends landmark research published by Dr. Blaser's lab in 2012 in Nature. That research showed that mice on a normal diet who were exposed to low doses of antibiotics throughout life, similar to what occurs in commercial livestock, packed on 10 to 15 percent more fat than untreated mice and had a markedly altered metabolism in their liver.

Among the unanswered questions in that study was whether the metabolic changes were the result of altered bacteria or antibiotic exposure. This latest study addresses the question by transferring bacterial populations from penicillin-exposed mice to specially bred germ-free, antibiotic-free mice, starting at three weeks of age, which corresponds to infancy just after weaning. The researchers discovered that mice inoculated with bacteria from the antibiotic-treated donors were indeed fatter than the germ-free mice inoculated with bacteria from untreated donors. "This shows us that the altered microbes are driving the obesity effects, not the antibiotics," says Dr. Cox.

Contrary to a longstanding hypothesis within the agricultural world that holds that antibiotics reduce total microbial numbers in the gut, therefore reducing competition for food and allowing the host organism to grow fatter, the team found that the penicillin did not, in fact, diminish bacterial abundance. It did, however, temporarily suppress four distinct organisms early in life during the critical window of microbial colonization:Lactobacillus, Allobaculum, Candidatus Arthromitus, and an unnamed member of theRikenellaceae family, which may have important metabolic and immunological interactions. "We're excited about this because not only do we want to understand why obesity is occurring, but we also want to develop solutions," says Dr. Cox. "This gives us four potential new candidates that might be promising probiotic organisms. We might be able to give back these organisms after antibiotic treatments."

The researchers worked with six different mouse models over five years to obtain their results. To identify bacteria, they used a powerful molecular method that involves extracting DNA and sequencing a subunit of genetic material called 16S ribosomal DNA. Altogether, the scientists evaluated 1,007 intestinal samples, which yielded more than 6 million sequences of bacterial ribosomal genes, the order of the nucleotides that spell out DNA. Studies like these are possible because of technological advances in high-throughput sequencing, which allows scientists to survey microbes in the gut and other parts of the body. The Genome Technology Center at NYU Langone Medical Center played a key role in identifying the genetic sequences in the study.






Rabu, 04 Januari 2017

Is Metabolic Neuropathy Much Different To Other Forms Of Nerve Disease


Today's post from nytimes.com (see link below) is an article that may help clear up one of the many problems people have with the language of neuropathy. A patient new to the disease may be diagnosed in terms that leave him or her bewildered and because the neurological vocabulary used by doctors is so broad, you may not be aware precisely what your diagnosis means in relation to other forms of neuropathy. Take the subject of this article for instance. You'd be forgiven for thinking that 'metabolic' neuropathy is a completely different form of nerve damage to other common neuropathies, when in fact it's another general term describing pretty much the same symptoms and problems that millions of others have. Metabolism (change) is life-sustaining chemical transformations within the cells of living organisms. There is an argument that all neuropathies are metabolic in nature but the word in itself shouldn't confuse you:- if you have metabolic neuropathy, you have neuropathy, in the same way that millions of others have. It's very often used in connection with diabetes and is therefore attached to diabetic neuropathy because that's the most common neuropathic cause. Diabetes is a metabolic disease, because it affects the body’s ability to capture glucose from food for use by the cells. You're probably more confused than ever now (I haven't explained it very well - apologies😓) but the symptoms and treatment are very much the same as other forms of neuropathy, peripheral or not and metabolic or not.


Metabolic Neuropathies
Metabolic neuropathies are nerve disorders that occur with diseases that disrupt the chemical processes in the body.

Causes

Nerve damage can be caused by many different things. Metabolic neuropathy may be caused by:

A problem with the body's ability to use energy, often due to a nutritional deficiency
Dangerous substances (toxins) build up in the body

Diabetes is one of the most common causes of metabolic neuropathies. People who are at the highest risk of nerve damage from diabetes include:

Those with damage to the kidneys or eyes
Those with poorly controlled blood sugar

Other common metabolic causes of neuropathies include:
Alcoholism
Low blood sugar (hypoglycemia)
Kidney failure
Porphyria
Severe infection throughout the body (sepsis)
Thyroid disease
Vitamin deficiencies (including vitamins B12, E, and B1)

Some metabolic disorders are passed down through families (inherited), while others develop due to various diseases.

Symptoms


These symptoms occur because nerves cannot send proper signals to and from your brain:
Difficulty feeling in any area of the body
Difficulty swallowing
Difficulty using the arms or hands
Difficulty using the legs or feet
Difficulty walking
Pain, burning, pins and needles, or shooting pains in any area of the body (nerve pain)
Weakness in the face, arms, legs, or other area of the body

Usually, these symptoms start in the toes and feet and move up the legs, eventually affecting the hands and arms.

Exams and Tests

An exam may show:

Decreased feeling (may affect touch, pain, vibration, or position sensation)
Reduced reflexes (most common in the ankle)
Muscles becoming smaller (atrophy)
Muscle twitches (fasciculations)
Muscle weakness
Loss of movement (paralysis)

Tests used to detect most metabolic neuropathies:

Blood tests
Electrical test of the muscles (EMG)
Electrical test of nerve conduction

Treatment

For most metabolic neuropathies, the best treatment is to correct the metabolic problem.

Vitamin deficiencies are treated with diet or injections. Abnormal blood sugar or thyroid function may need medication to correct the problem. Alcoholic neuropathy is treated with alcohol abstinence.

In some cases, pain is treated with medications that reduce abnormal pain signals from the nerves (duloxetine, gabapentin, pregabalin). Lotions, creams, or medicated patches can provide relief in some cases.

Clinical trials of new medications include antioxidants, neuroprotectants, insulin-like drugs, and aldose reductase inhibitors.

Weakness is often treated with physical therapy. You may need to learn how to use a cane or walker if your balance is affected. You may need special braces on the ankles to walk better.

Support Groups

For additional information and support, see www.neuropathy.org and http://diabetes.niddk.nih.gov/DM/pubs/neuropathies.

Outlook (Prognosis)

The outlook mainly depends on the cause of the disorder. In some cases, the problem can easily be treated. In other cases, the metabolic problem cannot be controlled and nerves may continue to become damaged.

Possible Complications 

 
Deformity
Injury to feet
Numbness
Pain
Trouble walking
Weakness

Prevention

Maintaining a healthy lifestyle can reduce the risk of neuropathy.
Avoid excess alcohol use.
Eat a balanced diet.
Visit the doctor regularly to find metabolic disorders before neuropathy develops.

If you already have a metabolic problem, regular doctor visits can help control the problem and reduce the chance of further nerve damage.

Patients who already have metabolic neuropathy can reduce the risk of some complications. A foot doctor (podiatrist) can teach you how to inspect your feet for signs of injury and infection. Proper fitting shoes can lessen the chance of skin breakdown in sensitive areas of the feet.


References

Shy ME. Peripheral neuropathies. In: Goldman L, Ausiello D, eds. Cecil Medicine . 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 446.

Montfort EG, Witte A, Ward K. Neuropathic Pain: A Review of Diabetic Neuropathy. US Pharm . 2010;35(5):HS8-HS15.

http://www.nytimes.com/health/guides/disease/metabolic-neuropathies/overview.html